Similar articles

• Metastatic differentiated carcinoma of the thyroid and radioiodine.

  Andrews JT, McGennisken MR. Andrews JT, et al. Australas Radiol. 1987 Feb;31(1):41-6. doi: 10.1111/j.1440-1673.1987.tb01780.x. Australas Radiol. 1987. PMID: 3619809 No abstract available.
• Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases.

  Taïeb D, Jacob T, Zotian E, Mundler O. Taïeb D, et al. Thyroid. 2004 Jun;14(6):465-7. doi: 10.1089/105072504323150804. Thyroid. 2004. PMID: 15242576
• Disseminated bone marrow metastases of insular thyroid carcinoma detected by radioiodine whole-body scintigraphy.

  Rufini V, Salvatori M, Saletnich I, Luzi S, Fadda G, Shapiro B, Troncone L. Rufini V, et al. J Nucl Med. 1996 Apr;37(4):633-6. J Nucl Med. 1996. PMID: 8691255
• [Utility and limits of nuclear medicine in the follow-up of differentiated thyroid carcinoma].

  Chiti A, Orunesu E, Rodari M. Chiti A, et al. Ann Ital Chir. 2006 May-Jun;77(3):215-22. Ann Ital Chir. 2006. PMID: 17137036 Review. Italian.
• Conventional withdrawal of thyroid hormone before radioiodine therapy in differentiated thyroid carcinoma: how frequently are adequately raised TSH levels attained?

  McLaughlin CM, Hunter SJ, Bell PM, McCance DR, Sheridan B, Atkinson AB. McLaughlin CM, et al. Clin Endocrinol (Oxf). 2008 Jul;69(1):169-70. doi: 10.1111/j.1365-2265.2007.03151.x. Epub 2008 Jul 1. Clin Endocrinol (Oxf). 2008. PMID: 18042175 Review. No abstract available.